The most widely used diagnostic criteria are those from the Diagnostic and statistical manual of mental disorders, 5th edition, text revision (DSM-5-TR).[2]American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.
https://www.psychiatry.org/psychiatrists/practice/dsm
The Schooler-Kane criteria are largely used for research purposes.[38]Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982 Apr;39(4):486-7.
http://www.ncbi.nlm.nih.gov/pubmed/6121550?tool=bestpractice.com
The Abnormal Involuntary Movement Scale and Impact-TD scale may be used to monitor severity of symptoms over time and impact on a patient's quality of life, respectively.[39]Chakrabarty AC, Bennett JI, Baloch TJ, et al. Increasing Abnormal Involuntary Movement Scale (AIMS) screening for tardive dyskinesia in an outpatient psychiatry clinic: a resident-led outpatient Lean Six Sigma initiative. Cureus. 2023 May;15(5):e39486.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10292174
http://www.ncbi.nlm.nih.gov/pubmed/37378259?tool=bestpractice.com
[40]Jackson R, Brams MN, Carlozzi NE, et al. Impact-Tardive Dyskinesia (Impact-TD) scale: a clinical tool to assess the impact of tardive dyskinesia. J Clin Psychiatry. 2022 Nov 28;84(1):22cs14563.
https://www.psychiatrist.com/jcp/impact-td-scale-to-assess-tardive-dyskinesia
http://www.ncbi.nlm.nih.gov/pubmed/36449471?tool=bestpractice.com
Diagnostic and statistical manual of mental disorders, 5th edition, text revision (DSM-5-TR)[2]American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.
https://www.psychiatry.org/psychiatrists/practice/dsm
DSM-5-TR describes the essential features of TD as abnormal, involuntary movements of the tongue, jaw, trunk, or extremities that occur in association with the patient using dopamine receptor-blocking agents. The involuntary movements must be present over a period of at least 4 weeks. The movements may vary in nature, but are distinct from the tremors seen in drug-induced parkinsonism.
The signs or symptoms develop during the patient's exposure to the dopamine receptor-blocking agent, within 4 weeks of withdrawal from an oral dopamine receptor-blocking agent, or within 8 weeks of withdrawal from a long-acting, injectable dopamine receptor-blocking agent.
The patient must have used the dopamine receptor-blocking agent for at least 3 months (or 1 month in patients ages >60 years).
Schooler-Kane criteria[38]Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982 Apr;39(4):486-7.
http://www.ncbi.nlm.nih.gov/pubmed/6121550?tool=bestpractice.com
For research purposes, the Schooler-Kane criteria for TD require all four of the following to be met:
At least 3 months of cumulative antipsychotic exposure
Mild dyskinesias in 2 or more body areas or moderate dyskinesias in one body area
Presence of movements for at least 3 months, and
No other identifiable etiologies of involuntary dyskinesias.
Abnormal Involuntary Movement Scale (AIMS)[39]Chakrabarty AC, Bennett JI, Baloch TJ, et al. Increasing Abnormal Involuntary Movement Scale (AIMS) screening for tardive dyskinesia in an outpatient psychiatry clinic: a resident-led outpatient Lean Six Sigma initiative. Cureus. 2023 May;15(5):e39486.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10292174
http://www.ncbi.nlm.nih.gov/pubmed/37378259?tool=bestpractice.com
A 12-item, validated rating scale to evaluate TD, developed by the National Institute of Mental Health.[39]Chakrabarty AC, Bennett JI, Baloch TJ, et al. Increasing Abnormal Involuntary Movement Scale (AIMS) screening for tardive dyskinesia in an outpatient psychiatry clinic: a resident-led outpatient Lean Six Sigma initiative. Cureus. 2023 May;15(5):e39486.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10292174
http://www.ncbi.nlm.nih.gov/pubmed/37378259?tool=bestpractice.com
It can be used to monitor the effects of long-term treatment with antipsychotics and the severity of TD over time. Items 1-7 assess involuntary movements across body regions. Score from 0 (no dyskinesia) to 4 (severe, maximal amplitude, and persistence during the observation of abnormal movements).[39]Chakrabarty AC, Bennett JI, Baloch TJ, et al. Increasing Abnormal Involuntary Movement Scale (AIMS) screening for tardive dyskinesia in an outpatient psychiatry clinic: a resident-led outpatient Lean Six Sigma initiative. Cureus. 2023 May;15(5):e39486.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10292174
http://www.ncbi.nlm.nih.gov/pubmed/37378259?tool=bestpractice.com
Items 8-12 assess global judgments, dental status, and nocturnal occurrence of movements.[39]Chakrabarty AC, Bennett JI, Baloch TJ, et al. Increasing Abnormal Involuntary Movement Scale (AIMS) screening for tardive dyskinesia in an outpatient psychiatry clinic: a resident-led outpatient Lean Six Sigma initiative. Cureus. 2023 May;15(5):e39486.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10292174
http://www.ncbi.nlm.nih.gov/pubmed/37378259?tool=bestpractice.com
Impact-TD[40]Jackson R, Brams MN, Carlozzi NE, et al. Impact-Tardive Dyskinesia (Impact-TD) scale: a clinical tool to assess the impact of tardive dyskinesia. J Clin Psychiatry. 2022 Nov 28;84(1):22cs14563.
https://www.psychiatrist.com/jcp/impact-td-scale-to-assess-tardive-dyskinesia
http://www.ncbi.nlm.nih.gov/pubmed/36449471?tool=bestpractice.com
A standardized clinician-rated instrument to assess the impact of TD on a patient's day-to-day life and functioning.[40]Jackson R, Brams MN, Carlozzi NE, et al. Impact-Tardive Dyskinesia (Impact-TD) scale: a clinical tool to assess the impact of tardive dyskinesia. J Clin Psychiatry. 2022 Nov 28;84(1):22cs14563.
https://www.psychiatrist.com/jcp/impact-td-scale-to-assess-tardive-dyskinesia
http://www.ncbi.nlm.nih.gov/pubmed/36449471?tool=bestpractice.com
It includes 4 domains:
Each domain is scored from 0 (no impact) to 3 (severe impact).[40]Jackson R, Brams MN, Carlozzi NE, et al. Impact-Tardive Dyskinesia (Impact-TD) scale: a clinical tool to assess the impact of tardive dyskinesia. J Clin Psychiatry. 2022 Nov 28;84(1):22cs14563.
https://www.psychiatrist.com/jcp/impact-td-scale-to-assess-tardive-dyskinesia
http://www.ncbi.nlm.nih.gov/pubmed/36449471?tool=bestpractice.com